Vijay Kale

ESTP Congress


Vijay P. Kale
Principal Scientist, Nonclinical Safety
Bristol Myers Squibb, New Jersey, USA.   

PhD, Molecular Toxicology, Penn State College of Medicine, Hersey, PA, USA  
M.V.Sc., Veterinary Pathology, S.D. Agricultural University, S.K. Nagar, India
B.V.Sc.& A.H., Bombay Veterinary College, Mumbai, India

Diplomate of American Board of Toxicology (DABT)
European Registered Toxicologist (ERT)    

Dr. Kale has over 13 years of experience in the nonclinical safety evaluation of novel therapeutic drugs. He is currently working as a Project Toxicologist/Principal Scientist at Bristol Myers Squibb, New Jersey. As a Project Toxicologist, he represents nonclinical safety function on the drug development projects for the products across various indications and modalities such as small molecules, protein degraders, and antibody drug conjugates.  Dr. Kale is responsible for formulating nonclinical safety assessment strategy in support of IND and NDA/BLA filing of the drugs in the US and rest of the world. Prior to joining BMS, Dr. Kale worked at Amgen, California as a Project Toxicologist. In this role he was responsible for designing strategies for nonclinical safety assessment of novel anticancer biologics (immuno-oncology) with various modalities such as monoclonal antibodies, proteins, and bispecific T cell engagers (BiTE®). Prior to Amgen, Dr. Kale worked as toxicology Study Director at Battelle Memorial Institute, Ohio and Zydus Research Center, Ahmedabad, India. At Zydus, he also served as Veterinary Clinical Pathologist leading the Clinical Pathology laboratory.  

He has authored 17 papers in peer reviewed journals, two book chapters, edited one book on cancer signaling, presented several abstracts/posters and delivered oral presentations at scientific meetings. He is a recipient of Outstanding Early Career Scientist Award by Association of Scientists of Indian Origin (ASIO)-SOT (2023), Best Publication Award by CTPVSS-SOT (2023), Outstanding Young Investigator Award (2021) and Student Achievement Award (2014) by Biotechnology Specialty Section of Society of Toxicology (SOT), SOT Science Communication Training Award (2021), International ToxScholar Outreach Grant Award (2016), Graduate Student Travel Award (2015) and Graduate Student Leadership Travel Award (2014, 2015) by SOT, and College of Medicine Class of 1971 Endowed Scholarship by Penn State College of Medicine (2014, 2015).

Dr. Kale is active in professional societies. He has served as a Board of Director representing early career scientists on Federation of American Societies for Experimental Biology (FASEB) board (2021-2023), Chair of Early Career Scientists Representative Engagement Task Force, FASEB (Jan-Dec 2022), Program Committee of American College of Toxicology (2020-2022), in the presidential chain (President, Past-President, VP, VP-Elect; 2018-2022) and as a councilor on ASIO-SOT executive council (2016-2018), Student Representative on Biotechnology Specialty Section of SOT (2013-2015), and Professional Development committee of Graduate Student Leadership of SOT (GSLC-SOT).